Description

Tirzepatide TFA (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide TFA has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neuromodulation–C225H348N48O68.xC2HF3O2—-[1]Fontanella RA, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024 Jan 29;22(1):114.|[2]Huang L, et al. Tirzepatide inhibits tumor growth in mice with diet-induced obesity. bioRxiv, 2023: 2023.06. 22.546093.|[3]Guo X, et al. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Front Pharmacol. 2023 Aug 28;14:1146960.—-4813.45 (free base)–98.84–CC[C@H](C)[C@@H](C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C(N[C@@H](C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC2=CNC3=CC=CC=C32)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(NCC(NCC(N4CCC[C@H]4C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N5CCC[C@H]5C(N6CCC[C@H]6C(N7CCC[C@H]7C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC(C(NC([C@H]([C@@H](C)CC)NC([C@H](CO)NC([C@H](CC8=CC=C(C=C8)O)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@@H](C)O)NC([C@H](CC9=CC=CC=C9)NC([C@H]([C@@H](C)O)NC(CNC([C@H](CCC(O)=O)NC(C(NC([C@H](CC=CC=C(C=C)O)N)=O)(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)(C)C)=O)=O)=O)=O.O=C(C(F)(F)F)O.[x]–Cancer; Metabolic Disease; Neurological Disease–10 mM in DMSO–GLP Receptor—-GPCR/G Protein–Peptides